Monitor glycemic control and detect early kidney disease
The DCA Vantage® Analyzer simplifies diabetes testing, delivering accurate,1 clinically relevant results during the patient visit to help physicians and nurses improve patient decision-making2,3 and diabetic patient compliance.4

Provide the clinical confidence your patients deserve
• Perform meaningful in-house tests, and take immediate action during the patient visit
• Clinical studies show that face-to-face testing along with direct physician-to-patient guidance significantly improves patient compliance
• Small blood sample size (1 µL) increases patient comfort

Manage your diabetes patients more effectively
Fast, actionable test results and powerful onboard patient management tools enable you to determine the effectiveness of a treatment plan, make therapeutic adjustments with greater confidence, and be certain that patients are complying with your recommendations.

Tighten glycemic control
Hemoglobin A1c (HbA1c) patient trending graphs give you the power to:
• Track a patient’s progression more comprehensively
• Detect even minor changes in HbA1c levels
• Recommend the most effective treatment plan

Monitor diabetes complications
The onboard GFR calculator indexes kidney function to help you:
• Monitor kidney disease progression
• Recommend the most effective treatment plan

Answers for life.
Make patient consultations more productive

The analyzer that physicians trust

Proven performance

- Robust technology highlighted in more than 100 clinical articles
- Used by three out of four physicians who perform HbA1c testing in the office
- One of just two point-of-care HbA1c analyzers that meet tightened NGSP performance criteria

A spectrum of dependable, quantitative results

- Flexible reporting of NGSP, IFCC, JCCLS, and Mono-S units
- HbA1c results can be reported as Estimated Average Glucose (eAG) values in the same, patient-friendly units (mg/dL) that home glucose meters display
- Patient-friendly eAG unit facilitates easier discussion and adjustment of the disease management program, and may help patients better manage their glycemic control

References:
5. GHX Market Intelligence, market data report. Q3 2009 Raw Data File.